

In the Claims

1. (currently amended) A method for treating infection ~~of~~ by feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT) and the nucleoside analog 3TC, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claims 2-3 (canceled)

4. (currently amended) The method according to claim 1, wherein ~~the transplanted cells~~ said bone marrow transplant comprises ~~are selected from the group consisting of allogeneic bone marrow cells and autologous cells.~~

5. (currently amended) A method for treating infection ~~of~~ by feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT), the nucleoside analog 3TC and an inhibitor of a retroviral protease, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claim 6 (canceled)

7. (original) The method according to claim 5, wherein said inhibitor of a retroviral protease is selected from the group consisting of HIV protease inhibitors and FIV protease inhibitors.

8. (previously presented) The method according to claim 5, wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

Claims 9-10 (canceled)

11. (currently amended) The method according to claim 5, wherein ~~the transplanted cells~~ said bone marrow transplant comprises ~~are selected from the group consisting of allogeneic bone marrow cells and autologous cells.~~

Claims 12-15 (canceled)

16. (previously presented) The method according to claim 1, wherein said azidothymidine or said nucleoside analog 3TC is administered as an oral or nasal formulation.

17. (currently amended) The method according to claim 1, wherein said azidothymidine or said nucleoside analog 3TC is administered by intravenous, intramuscular, or subcutaneous injection.

18. (currently amended) The method according to claim 1, wherein said azidothymidine or said nucleoside analog 3TC is administered in a dosage form selected from the group consisting of tablet, pill, powder, liquid solution or suspension, liposome, suppository, injectable, and infusible solution.

19. (previously presented) The method according to claim 1, wherein said FIV is a strain of FIV selected from the group consisting of FIV<sub>Pet</sub>, FIV<sub>Dix</sub>, FIV<sub>UK8</sub>, FIV<sub>Bang</sub>, FIV<sub>Aom1</sub>, FIV<sub>Aom2</sub>, and FIV<sub>Shi</sub>.

20. (previously presented) The method according to claim 5, wherein said azidothymidine, said nucleoside analog 3TC, or said retroviral protease inhibitor is administered as an oral or nasal formulation.

21. (previously presented) The method according to claim 5, wherein said azidothymidine, said nucleoside analog 3TC, or said retroviral protease inhibitor is administered by intravenous, intramuscular, or subcutaneous injection.

22. (previously presented) The method according to claim 5, wherein said azidothymidine, said nucleoside analog 3TC, or said retroviral protease inhibitor is administered in a dosage form selected from the group consisting of tablet, pill, powder, liquid solution or suspension, liposome, suppository, injectable, and infusible solution.

23. (previously presented) The method according to claim 5, wherein said FIV is a strain of FIV selected from the group consisting of FIV<sub>Pet</sub>, FIV<sub>Dix</sub>, FIV<sub>UK8</sub>, FIV<sub>Bang</sub>, FIV<sub>Aom1</sub>, FIV<sub>Aom2</sub>, and FIV<sub>Shi</sub>.

24 (new). The method according to claim 1, wherein said bone marrow transplant comprises autologous bone marrow.

25 (new). The method according to claim 5, wherein said bone marrow transplant comprises autologous bone marrow.